Skip to main
STRO

STRO Stock Forecast & Price Target

STRO Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sutro Biopharma is currently facing near-term risks related to clinical results for its lead ADC candidates, with potential downward adjustments in market penetration, higher discount rates, and longer time horizons to approval. However, the company's differentiated safety profile for its lead asset, STRO-004, as well as its strong pipeline of other potential treatments for a variety of tumor types, indicate long-term potential for significant earnings and revenue growth. With this in mind, a strong financial outlook and a discounted cash flow analysis, we have increased our price target for Sutro Biopharma to $50.

Bears say

Sutro Biopharma is a clinical-stage drug discovery, development, and manufacturing company with a negative outlook due to its early stage in the development process and potential regulatory and commercial risks. The company's promising drug candidate STRO-004 has shown encouraging early data but is still in dose optimization and has yet to demonstrate significant levels of efficacy or safety through clinical trials. Despite a strong financial position, the company may require additional equity financing and faces intense competition in the cancer therapeutic industry. The stock's current weaker valuation creates a potentially more attractive entry point, but it remains a high-risk investment.

STRO has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sutro Biopharma Inc (STRO) Forecast

Analysts have given STRO a Buy based on their latest research and market trends.

According to 9 analysts, STRO has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sutro Biopharma Inc (STRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.